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Background: Definite diagnosis of lymphangioleiomyomatosis (LAM) depends on either trans-
bronchial lung biopsy or video-assisted thoracic surgery, unless there is a history of chylothor-
ax, kidney angiomyolipoma (AML), or tuberous sclerosis complex (TSC). Vascular endothelial
growth factor-D (VEGF-D) was recently considered as a novel diagnostic marker for LAM.
Herein, we evaluated diagnostic value of serum VEGF-D in LAM patients.
Methods: Serum samples were obtained from 78 cases of LAM (50 definite and 28 probable LAM
based on European Respiratory Society guidelines), and 40 healthy female volunteers. VEGF-D
wasmeasured using enzyme-linked immunosorbant assay according to product instruction (R&D).
Results: Serum VEGF-D was significantly increased in definite LAM group, compared with that of
health control (median: 3841.9 pg/mL vs 405.5 pg/mL respectively, p < 0.001). The optimal cut-
off point for definite LAM diagnosis was 850.7 pg/mL. In probable LAM group, the majority of
patients (92.9%) had serum VEGF-D level over 850.7 pg/mL. The serum levels of VEGF-D in LAM
patientswith pulmonary cystic lesions only were lower than that in patientswith any of evidences69155039.
com (K.-F. Xu).
to this work.
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264 K.-F. Xu et al.of AML, chylous effusions, adenopathy, lymphangioleiomyomas, or TSC, but higher than that in
the health control. In addition, VEGF-D levels were correlated with disease severity measured
as LAMCT grade, andpresentations of chylous effusions and/or lymphatic involvement (p< 0.05).
Conclusion: Serum VEGF-D should be added to the current diagnosis algorithm to enhance defin-
itive diagnosis for LAM.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Lymphangioleiomyomatosis (LAM) is a rare destructive
cystic lung disease in women. The final pathological diag-
nosis is often needed for diagnosis of LAM unless a history of
chylothorax, or kidney angiomyolipoma (AML), or tuberous
sclerosis complex (TSC) is found, which is accompanied by
typical clinical and radiological presentations.1 While
invasive biopsy via bronchoscopy or video-assisted thor-
acoscopic surgery is safe and reliable diagnostic approach
for untypical cases, these invasive procedures caused
complications in certain cases. Also, these procedures are
not the best choice in screening for LAM in high-risk pop-
ulations. Routine screening of LAM in female patients with
spontaneous pneumothorax is cost-effective.2 In adult
female patients with TSC, prevalence of LAM is up to one
third.1 High resolution computed tomography (CT) could
detect suspected LAM cases, but still need to be confirmed
by invasive lung biopsy. Clinical application of invasive
procedures may not be acceptable in some patients.
Furthermore, delayed diagnosis could cause negative
impact for patients if they wish to use therapy with
mammalian target of rapamycin (mTOR) inhibitors.1,3
There is no diagnostic blood test for LAM until 2006 when
serum vascular endothelial growth factor-D (VEGF-D) was
reported elevated in patients with LAM.4 Consequent
studies confirmed the potential value of serum VEGF-D in
diagnosis of LAM.5e7 Serum VEGF-D has been used as
a diagnostic criterion for LAM in a randomized, placebo-
controlled, double-blinded clinical trial (MILES).3 It is of
interest that serum levels of VEGF-D were decreased after
effective treatment of sirolimus, an mTOR inhibitor, in
clinical trials.3,8 However, there is no consensus in the
application of VEGF-D in diagnosis for LAM. Herein, we
tested potential diagnostic role of VEGF-D in our patient
population in according to the European Respiratory Society
(ERS) guidelines for LAM.1 The study focused on application
of VEGF-D for diagnosis of LAM. According to ERS guidelines
for LAM, LAM could be diagnosed as definite LAM, probable
LAM, or possible LAM. The diagnostic potential of VEGF-D
was examined not only in patients with definite or prob-
able LAM, but also in sub-group of patients without clinical
supporting evidences other than cystic lung lesions, such as
AML, chylous effusions, lymphatic involvements (adenop-
athy or lymphangioleiomyomas), or TSC.
Materials and methods
Study populations
The protocol of this research was approved by the Institu-
tional Review Board of Peking Union Medical CollegeHospital, China. The patients enrolled in this study fulfilled
the requirements of definite or probable LAM diagnosis
criteria of ERS1 between 2009 and 2011 in Peking Union
Medical College Hospital. Signed informed consent forms
were obtained from all patients. There were 50 cases of
definite LAM and 28 probable LAM patients. Among them,
31 patients from definite (11/50, 22.0%) or probable (20/
28, 71.4%) groups were labeled as lone LAM sub-group
defined as highly suspected LAM without other supporting
clinical evidences, such as chylous effusions, AML, TSC, or
lymphatic involvement.7 Patients were excluded if they did
not meet the criteria of diagnosis of LAM, or lack of medical
history or blood samples.
Forty age-matched healthy female volunteers were
enrolled as the control. All healthy volunteers presented
normal chest radiography without any history of respiratory
diseases, or other significant medical history or laboratory
abnormalities. All participants provided signed informed
consent.
Clinical data
All required data about the diagnosis and other assessments
were obtained. The following data were included: Borg scale
of breathlessness, St George’s Respiratory Questionnaire
(SGRQ), blood gas analysis on room air, lung function
(spirometry, lung volume, and diffusion capacity), six
minutes walking distance (6MWD), and CTof chest, abdomen
and pelvis. Technical standards of these were based no
previous reports.9e13 LAM chest CT was visually scaled to
three groups based on other report.14 Cyst involvement less
than one third is Grade I, between one third and two thirds is
Grade II, and two thirds or more is Grade III.
VEGF-D assay
Peripheral fasting blood samples were collected with serum
separator tubes. Sera were separated and saved in 80 C
before testing for VEGF-D levels, whichweremeasured using
enzyme-linked immunosorbant assay kit according to the
instruction from the manufacturer (R & D Systems, Minne-
apolis, MN). The range of measurements is 0e4000 pg/mL.
Levels over 4000 pg/mL were recorded as 4000þ pg/mL.
Statistical analysis
Serum VEGF-D levels were expressed as median and inter-
quartile range (IQR) of 25%e75%. Statistical comparisons of
serum VEGF-D levels among different groups were per-
formed by ManneWhitney U test for comparison between
two groups. A receiver operating characteristic (ROC) curve
was applied for obtaining optimal cut-off value of serum
VEGF-D in diagnosis for LAM 265VEGF-D. Binary logistic analyses of correlations were
measured between VEDF-D and following variables: arterial
partial pressure of oxygen at room air, SGRQ total scores,
Borg scale of breathlessness, 6MWD, forced expiratory
volume at 1 s (FEV1), force vital capacity (FVC), total lung
capacity, diffusion capacity of lung for carbon monoxide
(DLCO), kidney AML, and combined chylous effusions and/
or lymphatic involvements (adenopathy or lymphangio-
leiomyomas). Differences were considered to be statisti-
cally significant at p value less than 0.05. Analyses were
performed by SPSS 11.0 software.
Results
Characteristics of subjects
According to ERS guidelines for LAM,1 50 cases of definite
LAM diagnosis were achieved based on typical clinical and
radiological presentations, and either of pathological
diagnosis of lung tissue (25 cases) or postperitoneal mass (6
cases), or history of chylothorax (20 cases) or chylous
ascites (6 cases), or AML (15 cases), or TSC (2 cases). Mean
ages from the definite LAM and the health control groups
were 40.8  8.0 and 41.4  8.5 (mean  SE) years old
(p > 0.05). Seven of fifty definite LAM patients received
sirolimus when blood was drawn. The characteristics of
subjects in definite and probable LAM are listed in Table 1.
Serum VEGF-D levels were increased in LAM
patients
The median value of serum VEGF-D in health and definite
LAM was 405.5 pg/mL (IQR 245.3e527.8 pg/mL), and
3841.9 pg/mL (IQR 2490.6e4000þ pg/mL) respectively.
Serum VEGF-D levels were significantly increased in the
definite LAM patients compared with the health control
(p < 0.001) (Fig. 1). The area under the ROC curve was
0.999  0.002 (95%CI 0.995e1.000) (p < 0.001) (Fig. 1). The
sensitivity and specificity of the optimal cut-off valueFigure 1 Serum VEGF-D levels are elevated in the diagnosed LA
VEGF-D levels in the definite LAM, and health control. (B) ROC cu
representing the sensitivity of 96.0% and specificity of 100.0%.850.7 pg/mL were 96.0% and 100.0% respectively. At this
cut-off point, the sum of the sensitivity and specificity was
the highest.
Serum VEGF-D levels were increased in lone LAM
patients
There was a trend of difference in serum VEGF-D levels
between definite and probable LAM patients. The median
value of serum VEGF-D in these two groups was 3841.9 pg/
mL (IQR 2490.6e4000þ pg/mL) and 2695.8 pg/mL (IQR
1558.4e3979.6 pg/mL) respectively (p > 0.05). In this
study, lone LAM patients were found in 22.0% definite LAM
group and 71.4% probable LAM group. We showed that
levels of serum VEGF-D in lone LAM patients were lower
than that in non-lone LAM patients. The median of serum
VEDF-D in lone LAM was 2227.6 pg/mL (IQR 1258.6e3753.0)
compared with 4000þ pg/mL (IQR 3029.0e4000þ pg/mL)
from non-lone LAM patients (p Z 0.001). However, VEGF-D
in the lone LAM group was still significantly higher than that
in the health control group (p < 0.0001). Based on data
from definite LAM and healthy volunteers, the ROC curve
area for diagnosis of lone LAM was 0.998  0.004 (95%CI
0.990e1.000) (p < 0.001). The optimal cut-off value for
lone LAM was 726.5 pg/mL.
VEGF-D and CT grade
VEGF-D levels were significantly higher in Grade III patients
than that in Grade I or II in the definite LAM patient group
(Fig. 2A) (p < 0.01) or combined definite and probable LAM
patient groups (Fig. 2B) (p < 0.001). There was a trend of
increase in VEGF-D levels in Grade II than that in Grade I,
but no statistical significance. VEGF-D levels less than
850.7 pg/mL were found in two cases of definite LAM
patients. Both of them were Grade I (Fig. 2C as an
example). In probable LAM group, two cases presented
VEGF-D less than 850.7 pg/mL, one in Grade I and one in
Grade III. Overall, severity of disease measured by CT grade
apparently had significant impact on VEGF-D levels.M compared with the health control. (A) Comparison of serum
rve for definite LAM. An optimal cut-off value is 850.7 pg/mL,
Figure 2 Relationship between serum VEGF-D levels and CT grades in patients with LAM. Serum VEGF-D levels were significantly
higher in Grade III than that in Grade I or II in the definite LAM patients (2A) or combined the definite and the probable LAM patients
(2B). There was a trend but not significant difference of VEGF-D levels between CT Grade I and II groups. Fig. 2C showed a typical
CT grade I with scattered cysts pathologically confirmed as LAM via transbronchial lung biopsy. The VEGF-D level in this patient was
only 726.5 pg/mL. Fig. 2D showed a typical CT grade III with diffuse cystic changes throughout all lung fields. The serum VEGF-D was
over 4000 pg/mL.
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VEGF-D levels were correlated with combined chylous
effusions and/or lymphatic involvement (p < 0.05). There
were no significant correlations between VEGF-D levels and
arterial partial pressure of oxygen at room air, SGRQ total
scores, Borg scale of breathlessness, 6MWD, FEV1, FVC,
total lung capacity, DLCO, or kidney AML (p > 0.05).Discussion
We confirmed the diagnostic value of serum VEGF-D for
LAM. VEGF-D is also valuable in diagnosis for lone LAM
without chylous effusion, AML, lymphatic involvements, or
combining with TSC. At the cut-off point of 850.7 pg/mL,
the sensitivity and specificity for LAM are 96.0% and 100.0%
in this report. Although there is no consensus in cut-off
point of VEGF-D for LAM, a value at 800 pg/mL has been
suggested as a cut-off point in diagnosis of LAM7 and
applied in inclusion criteria of MILES study as well.3 In one
study reported 111 cases of LAM and 40 healthy volun-
teers, with 3% and 10% Asian or Pacific islander in LAM and
control groups respectively, the mean value of VEGF-D in
health control was 657  43 pg/mL.5 The discrepancy of
serum VEGF-D values reported from different centers maybe due to some differences in sample collections, manip-
ulations, and environment of laboratory. It was also re-
ported that sample storage for over 3 months increased
VEGF-D reading.15 It is important to verify the protocol
and cut-off points used in different laboratories to maxi-
mize sensitivity and specificity in the patient population
studied.
Clinical diagnosis of LAM is currently based on ERS
guidelines.1 However, there is high potential to include
VEGF-D blood test in algorithm for LAM diagnosis, especially
for probable LAM.1 One study showed that VEGF-D blood
test could help to increase the possibility of LAM diagnosis
from highly suspected LAM patient.7 A high percentage in
suspected LAM could be classified to lone LAM without
supporting features other than diffuse pulmonary cystic
changes. It was reported that serum VEGF-D level was
increased only in those with lymphatic involvements (with
positive adenopathy or lymphangioleiomyomas).5 Thus, it
was also important to test the diagnostic value of VEGF-D in
lone LAM in our study. Our results suggested that serum
VEGF-D was reliable in diagnosis for lone LAM, which was
consistent with a previous report.7 If VEGF-D serum test
could be added in diagnostic criteria of definite LAM, the
majority of probable LAM patients (26/28, 92.9%), or lone
LAM patients (28/31, 90.3%) might avoid invasive diagnostic
procedures. We believe that this might change the current
Table 1 Characteristics of patients with definite and probable LAM.
Definite LAM (N Z 50) Probable LAM (N Z 28)
Age (year) 40.8  7.9 42.2  8.3
SGRQ total 47.62  22.87 55.30  22.52
Borg scale of breathlessness 2.70  2.43 3.26  2.64
6MWD (m) 422.47  129.72 404.63  112.26
PaO2 (mmHg) 72.78  14.73 73.57  14.29
FEV1 (% predicted) 64.45  27.33 51.92  31.34
FVC (% predicted) 85.70  20.36 77.68  23.20
TLC (% predicted) 113.37  21.51 114.44  23.85
DLCO (% predicted) 48.69  21.85 40.95  20.15
Value expressed as mean  SE, none of variables listed shows significant difference between two groups (p > 0.05). SGRQ, St George’s
Respiratory Questionnaire; 6MWD, six-minute walking distance; PaO2, arterial partial pressure of oxygen; FEV1, forced expiratory volume
in 1 s; FVC, forced vital capacity; TLC, total lung capacity; DLCO, diffusion capacity of lung for carbon monoxide.
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patients might get definite diagnosis without invasive
procedures. This will substantially reduce the medical costs
and improve the quality of care for LAM patients.
There are two cases with VEGF-D less than 850.7 pg/mL
in definite LAM patients who had Grade I cystic changes
suggesting the impacts of disease severity on influencing
VEGF-D levels. Our findings supported the previous report
that the LAM CT grade is a determinant of VEGF-D levels.5
Thus, physicians should keep in mind that patients with
mild severity on CT scan may have normal ranges of serum
VEGF-D. Of notes, normal values of serum VEGF-D could not
exclude diagnosis of LAM. Invasive diagnostic procedures
could be carefully weighted to those with probable LAM and
normal range of serum VEGF-D. More studies are required
to investigate the role of VEGF-D in differential diagnosis of
diffuse cystic lung diseases.
Serum levels of VEGF-D were reported to be correlated
with some clinical measures. For example, DLCO and DLCO/
alveolar volume were reported to be correlated with VEGF-
D, although decline rate of DLCO was not correlated with
VEGF-D.5 In the report including 111 cases of LAM, no
correlation was found in VEGF-D and FEV1, FVC, FEV1/FVC,
residual volume, total lung capacity, or decline rate of
FEV1.
5 However, another report found significant correla-
tion between VEGF-D and DLCO/alveolar volume or FEV1/
FVC.4 In this study, we found a correlation between VEGF-D
and combined chylous effusions and/or lymphatic involve-
ment, but not with other variables, such as arterial oxygen,
SGRQ quality of life, Borg scale of breathlessness, 6MWD,
pulmonary functions (FEV1, FVC, total lung capacity and
DLCO), and kidney AML. The possible limited sample size
may not detect potential correlations. We agree to the
notion that lymphatic involvement determines VEGF-D
levels.5,15 However, controversial reports were found
regarding AML. One study found that serum VEGF-D levels
was positively correlated with size of AML,8 while negative
or neutral correlations of VEGF-D and AML were also re-
ported.5,7,15 Data from our report support that VEGF-D
levels are correlated with CT grade of severity and exis-
tence of chylous effusions and/or lymphatic involvement.
Recent clinical trials have demonstrated a decrease in
VEGF-D level after sirolimus treatment, along with favor-
able responses in patients with LAM or TSC,3,8 which again
supports relationship of VEGF-D levels and disease severity.VEGF-D, acts as a lymphangiogenic growth factor, may
reflect the burden of LAM cells in human body. LAM cells
produce VEGF-C and VEGF-D, which are involved in LAM cell
proliferation and lymphangiogenesis via VEGFR3.16 Lym-
phangiogenesis is critical in development of LAM foci.17
There is extensive lymphatic vessel network in LAM foci.17
Although both VEGF-C and VEGF-D are highly expressed in
smooth muscle-like cells, only VEGF-D is elevated in
serum.4 Clinical observation suggested that increased
VEGF-D is a sign of lymphatic involvements.5 Analyses of
data from MILES study found that VEGF-D levels could be
used in predicting treatment response to sirolimus and
disease progression.18 Regarding critical role of VEGF-D in
lymphangiogenesis and LAM development, serum VEGF-D
might be considered as not only a diagnostic biomarker,
but also a potential target for LAM treatment.19
We should point out the limitation of lack of control of
other cystic lung diseases or cancer patients in this study. It
was reported that VEGF-D is not increased in patients with
other cystic lung diseases, such as emphysema, Langerhans
cell histiocytosis, Sjo¨gren syndrome with cystic changes in
lung, and BirteHoggeDube´ syndrome.6 More studies are
required to confirm this. Serum VEGF-D was reported to be
elevated in some type of cancers and regarded as
a biomarker of metastasis.20,21 However, serum levels of
VEGF-D in cancer and their potential role have not been
systemically investigated. Nevertheless, cancer from
different origins should be considered in differential diag-
nosis when we use VEGF-D in diagnosis of LAM.
In summary, our results show that the serum VEGF-D
level is significantly increased in LAM patients. As a power-
ful diagnostic tool for LAM, determining the serum VEGF-D
should be considered to add to the current diagnostic
algorithm before recommending invasive diagnostic proce-
dures. In addition, serum VEGF-D may be applied in
screening high-risk population, monitoring of severity and
predicting treatment response in LAM patients, and may be
a potential target in LAM treatment.Acknowledgments
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